about
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosisThe plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategiesMouse aortic ring assay: A new approach of the molecular genetics of angiogenesisThe pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependentDUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase.Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells.Identification of a novel frameshift mutation in the ILDR1 gene in a UAE family, mutations review and phenotype genotype correlation.Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells.Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activationEndothelial cell intracellular Ca2+ concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migrationHuman breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expressionHost-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growthCorrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin
P50
Q24319106-35C57A86-8561-438A-9600-8E1E04BAC9D5Q24671642-43B007DD-1A11-40DF-A5F2-7097922B7E2CQ24797401-4FE7C11A-3938-47FA-A9BD-6DB46204B417Q28593487-A5D130FC-5349-4244-B099-496468A6F27DQ30579145-4350E967-5FEE-4E9F-9A66-C1CCE6EAA576Q34725029-5435EBB9-7123-4676-9E23-E3E9F6C32341Q40997749-3E1C5175-6113-4F92-90B7-89797CE86E85Q42146170-DE72AA3C-0782-48F9-B446-79207D018835Q42445208-FD264442-2B1C-4D3D-AFAE-76E1748FB7C7Q47697374-FCCC8537-55D5-4807-AA5F-A44043D7809EQ48301035-800115A3-7A28-435A-B4B6-DC9F9F2B853CQ73194343-1BC107B5-F9EF-47B5-83CA-5DE3B7248F98Q74313513-CEAD196D-2AE0-48EA-9A12-DF5FF66DADBDQ74479649-A8517A95-B79F-4519-81C8-510B932BAD64Q80402725-3596EF4D-1A81-4FAB-931D-EC35B57CAEBAQ87262698-3570D394-107D-4DAC-9CB6-1BE58B675B1A
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5529-9228
@en
name
Khalid Bajou
@ast
Khalid Bajou
@en
Khalid Bajou
@es
Khalid Bajou
@nl
type
label
Khalid Bajou
@ast
Khalid Bajou
@en
Khalid Bajou
@es
Khalid Bajou
@nl
prefLabel
Khalid Bajou
@ast
Khalid Bajou
@en
Khalid Bajou
@es
Khalid Bajou
@nl
P106
P1153
6601960766
P31
P496
0000-0002-5529-9228